1. Home
  2. OCG vs CVKD Comparison

OCG vs CVKD Comparison

Compare OCG & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oriental Culture Holding LTD

OCG

Oriental Culture Holding LTD

N/A

Current Price

$1.54

Market Cap

3.3M

ML Signal

N/A

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

N/A

Current Price

$1.71

Market Cap

3.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OCG
CVKD
Founded
2018
2022
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
3.4M
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
OCG
CVKD
Price
$1.54
$1.71
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $14.00
AVG Volume (30 Days)
19.1K
★ 103.3K
Earning Date
11-03-2026
11-16-2026
Dividend Yield
★ 10.27%
N/A
EPS Growth
N/A
★ 23.94
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.01
$0.82
52 Week High
$19.29
$12.50

Technical Indicators

Market Signals
Indicator
OCG
CVKD
Relative Strength Index (RSI) 43.07 66.44
Support Level $1.46 $0.88
Resistance Level $1.93 $2.23
Average True Range (ATR) 0.11 0.21
MACD -0.01 0.07
Stochastic Oscillator 18.97 78.44

Price Performance

Historical Comparison
OCG
CVKD

About OCG Oriental Culture Holding LTD

Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. The company generates revenue through listing service fees, transaction fees, and other revenues collected from traders.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: